MZT2B and non-small cell lung carcinoma: Complementing this, receiver operating characteristic (ROC) curve analysis highlighted the robust predictive capability of MZT2B expression for NSCLC prognosis, yielding an area under the curve (AUC) of 0.838 (95% CI: 0.807–0.868) (Fig. 1L).